Johnson & Johnson has begun the final stage of clinical trials for their coronavirus vaccine candidate. They are the fourth company to begin Phase 3 testing of a potential vaccine, joining Moderna, Pfizer/BioNTech, and AstraZeneca.
Johnson & Johnson's vaccine is different than the other three, as it only requires a single dose. The other vaccines require two doses administered a few weeks apart. Another advantage of Johnson & Johnson's vaccine is that it does not need to be refrigerated at sub-zero temperatures, making it easier to store and transport around the country.
The clinical trial will be the largest to date, with over 60,000 adult participants.
"This is an unprecedented feat for the scientific community made possible by decades of progress in vaccine technology and a coordinated, strategic approach across government, industry, and academia," he said. "It is likely that multiple COVID-19 vaccine regimens will be required to meet the global need. The Janssen candidate has showed promise in early-stage testing and may be especially useful in controlling the pandemic if shown to be protective after a single dose."
Johnson & Johnson is also working on a vaccine that requires two doses and is planning to run a Phase 3 clinical trial in the United Kingdom.
Photo: Getty Images